(Q38211832)

31 August 2017

title

The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space (English)

1 reference

31 August 2017

1 reference

Ashish Kumar Kakkar

1

1 reference

31 August 2017

Neha Dahiya

series ordinal

2

1 reference

31 August 2017

publication date

14 May 2014

1 reference

Drug Development Research

31 August 2017

published in

1 reference

31 August 2017

volume

75

1 reference

31 August 2017

issue

4

1 reference

31 August 2017

page(s)

231-234

1 reference

Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products

31 August 2017

cites work

1 reference

Accelerating access to treatments for rare diseases

21 January 2018

1 reference

Two decades of orphan product development

21 January 2018

1 reference

Translation of rare disease research into orphan drug development: disease matters

21 January 2018

1 reference

Orphan drug development: an economically viable strategy for biopharma R&D.

21 January 2018

1 reference

Incentives for orphan drug research and development in the United States

21 January 2018

1 reference

Pricing and reimbursement of orphan drugs: the need for more transparency

21 January 2018

1 reference

Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

What is wrong with orphan drug policies?

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Assessing the economic challenges posed by orphan drugs

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/DDR.21176

1 reference

31 August 2017

1 reference